This is reflected by guidelines on breast cancer risk management in BRCA1/BRCA2 carriers, which do not give clear recommendations for women with a previous diagnosis of ovarian cancer, but support discussion of the option of risk-reducing breast surgery with women on a case-by-case basis (NCCN, 2016). The gene discussed is BRCA2; the disease is breast carcinoma.